efimosfermin - Search News

News

GSK, liver disease and efimosfermin

GSK to acquire liver disease drug Efimosfermin for up to USD 2 billion

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, have announced that they

Medical Dialogues · 15h

PMLive · 14h

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

· 1d · on MSN

GSK to buy liver disease drug for up to $2 billion

1don MSN

GSK to buy efimosfermin for up to $2 billion

British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine ...

Pharmabiz21h

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

Medscape6d

Once-Monthly Efimosfermin Leads to Significant MASH Improvement in Phase 2 Trial

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

GSK, liver disease and efimosfermin

Trending now